Hey Pal, long time no talk. I monitor most boards far less frequently than I used to, so it's harder to keep in touch. Anyway, I certainly look forward to hearing from you, esp. your current take on stocks we've discussed before. Below is a thumbnail sketch of where I'm at:
COCN - didn't listen to my own advice and bought in too soon. Now, it's so damn oversold, I'm loathe to sell even though buying a non-marginable stock wasn't a good idea. When taking a long-term view, I don't mind too much that they'll do the Ph2b migraine by themselves, 'cause they'll get it done faster. If they get good results, surely the stock should break out way above current levels.
IPIC - Am simply not tempted, not even at these prices. Just too gun-shy to jump in before results are released for Pagaclone and others. Certainly seems massively oversold, but will likely con't to be "dead money" till Pagoclone results. Might be tempted to get back in before Pagoclone results if further Redux studies are positive. Am losing faith in Bextra.
PARS - Bought in last month. Another non-marginable stock - my money management has been woeful as of late. Will sit on it 'till release of HU-211 results or shortly thereafter. Am wondering how much publicity they'll get with good results. I'd think the drug would be extrememly attractive to any potential partner.
IMNR - If I could only own 1 stock, this is it. Wish I had the cash to be seriously overweighted here. You'd be interested in my recent post (6/15) on "approaching the point of inevitability". Lots of short-term similarities to the pre-Redux/post-Redux IPIC story. You should seriously check this one out. FAST.
SUPG - this one completes my current portfolio. Again, if I had more cash, I'd buy more. Story is a bit longer-term, but there are a lot of ways to win with this. You have time to check this one out. I'm betting on Rubinfield and Ellison. Had outstanding Ph2 cancer results that went virtually unnoticed.
CYP - Happy to sit on the sidelines. I've posted a lot there.
UMED - Would be my next "new buy". The NTZ fiasco makes the FDA look pretty bad again. However, that was only their 4th or 5th most important product at best. This is a very well-kept secret. Of all the stocks I follow, it now has the best projected appreciation based on discounted earnings.
GLIA - getting to be attractively priced. Hope to get it cheaper, but there is a lot to like here.
AXPH - recently bought some for the kids. All of the "technology" companies have gotten killed lately (only a few deserved it) - e.g., ARQL, ABSC, AXPH, PCOP. If I owned 10 stocks, some of these would be included.
NPSP - Sort of tempted. The daily volume is sickly though and even in best-case scenario earnings are too far off.
NBIX, SNAP, NRGN, TTNP - my opinions haven't changed here. I like TTNP the best, but need to get some more facts about Iloperidone's dev'l. Too, they need a partner for at least one of their cancer drugs. NRGN has had more failures than any company I know. SNAP has a lot riding on the migraine drug. NBIX is still a ways off from having serious efficacy data on any drug aside from the DHEA.
I'm having a lousy '98 YTD. Damn,I just have much less time to spend on following stocks. My list of those actively followed con't to get weeded down. However, everytime I take a fresh look at my portfolio, I like each of the stocks a lot.
Back to you. No rush - I'll be at a conference from Wed - Sun. I'll look for your reply in the usual places, or trace it through Yahoo Search. Hope all is well with you (and your portfolio).
Hey Shahar, it's great to hear from you. Like you, I've been way too busy to spend much time following the message boards. However, I have done quite a bit of investing over the past few months. I'm a pretty big fan of internet related issues so I decided to do some investing in that area. I'm glad that I did as it has made a world of difference to my bottom line. However, I'm still also very active in some biotech issues. Like you, I'm scared of IPIC. Things just don't look good. I'm also not too crazy about the recent insider selling activity. Even a slight hint of Redux damage could send the stock much lower. I'm way out for now. I may get brave in August and bet on phase II Pagaclone results. We'll have to wait and see. I'm very tempted to buy more COCN. I really don't see any reason to think that it won't rebound to the $3 level in the near future. I'll be shocked if it continues to drop. Do you know when they plan to initiate their phase I anxiolytic trial? I've heard no news. I may have to contact the company. TTNP is my favorite of all the biotech stocks. See my most recent post to Lelim. In short, Ipoeridone is perfectly situated to become a dominant player in the antipsychotic market. If you haven't heard, Ziprasidone was rejected by the FDA and additonal info is needed. This could be something very minor or something major. If Ziprasidone isn't approved the market is gigantic for Iloperidone. Sertindole is now out of the running and Seroquel is associated with some pretty serious health risks. Iloperidone's chances are looking better and better with each passing day. OF course, the delay in cancer trials has me concerned. I'm keeping a close eye on TTNP. I'm staying away from SNAP, NRGN, and NBIX for now. I need to see some serious progress before I get in. I do like Sibia. I'm looking into taking a possible position there. Just a short term play. I actually don't know too much about the other biotechs that you mentioned. I guess I haven't been doing my homework. Thanks for the advice on IMNR. I'll check it out. I'm also looking into UMED. I dumped my shared in MCHM as I'm finding it to be one of the most lucrative stocks to buy and sell for quick gains. I'm out for now, but will buy back in soon. I'm really liking GLIA. How low do you think it will go? The offering of additonal shares hasn't been seen as a positive move by investors. I hear that Gliatech may be relacating to my neck of the woods(RTP, North Carolina). If so, it is likely that I will be able to get a lot of dirt on the company. I'm pretty active in the scientific community and usually get the scoop on local companies. Not insider stuff, but solid info on the potential of many of these companies. I'll be sure to pass anything on that may be helpful to you. Well, I gotta run. It was great to hear from you and take care. Talk to you later.